(Cornell University) A new class of biomaterial developed by Cornell researchers for an infectious disease nanovaccine effectively boosted immunity in mice with metabolic disorders linked to gut bacteria – a population that shows resistance to traditional flu and polio vaccines.
Original source: https://www.eurekalert.org/pub_releases/2019-03/cu-nbi032819.php